Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

sumgenbio.com

Founded Year

2015

Stage

Series B - II | Alive

Total Raised

$71.02M

Last Raised

$31.38M | 9 mos ago

About SUMGEN

SUMGEN is an innovation-driven biopharmaceutical company dedicated to the development and commercialization of innovative antibody drugs for major diseases such as malignant tumors.

SUMGEN Headquarters Location

Room 301, 3rd Floor, Building 2, Binan Road No.688, Changhe Street Binjiang District

Hangzhou, Zhejiang ,

China

+86-0571-87961799

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing SUMGEN

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SUMGEN is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

SUMGEN Patents

SUMGEN has filed 2 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/16/2019

Clusters of differentiation, Immune system, Transcription factors, Immunology, Human proteins

Application

Application Date

4/16/2019

Grant Date

Title

Related Topics

Clusters of differentiation, Immune system, Transcription factors, Immunology, Human proteins

Status

Application

Latest SUMGEN News

Sumgen Completes $32 Million Round for Immunotherapy Antibodies

Oct 1, 2020

publication date: Oct 1, 2020 Sumgen Biotech of Hangzhou completed a $32 million Series B funding round to advance its portfolio of novel immunotherapy antibodies. The round was led by Addor Capital and co-led by Cowin Capital and Sinowisdom Investment. The proceeds will be used to fund clinical trials of the company's pipeline of ten oncology mAbs and construction of an antibody production facility in Hangzhou Share this with colleagues: Sorry this page is available to subscribers only. If you're not a subscriber why not subscribe today? If you are already a subscriber, please login. If you believe you should have received this message in error, please contact us .

  • When was SUMGEN founded?

    SUMGEN was founded in 2015.

  • Where is SUMGEN's headquarters?

    SUMGEN's headquarters is located at Room 301, 3rd Floor, Building 2, Binan Road No.688, Changhe Street, Hangzhou.

  • What is SUMGEN's latest funding round?

    SUMGEN's latest funding round is Series B - II.

  • How much did SUMGEN raise?

    SUMGEN raised a total of $71.02M.

  • Who are the investors of SUMGEN?

    Investors of SUMGEN include Addor Capital, Wuxi Shangtong, Hankang Equity Investment Management, ZheShang Venture Capital, Junchuan Capital and 10 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.